Clinical trial news

SMA patients and clinical trials

Key SMA Patient Trial of Skeletal Muscle Activator Getting Underway

Cytokinetics has announced additional details about a planned Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). Investigators believe CK-2127107, a skeletal muscle activator, has the potential to improve muscle function, either alone or in combination with other drugs. The company, in collaboration with its partner Astellas, recently held…

process

Isis Pharmaceuticals Announces Open-Label Extension Study SHINE in Pediatric SMA Patients

Isis Pharmaceuticals, Inc. recently announced the official launch of an open-label extension study, called SHINE, which will be continuing treatment of the same infants and children diagnosed with spinal muscular atrophy (SMA) who had previously participated in Phase III studies ENDEAR and CHERISH. The infants whi had participated in ENDEAR will continue to…

Update on Ongoing Clinical Trials for SMA Drug Programs

The Annual SMA Conference organized by Cure SMA was recently held this June in Kansas City. According to a news release, six representatives out of the seven drug programs currently being assessed in clinical trials presented their work at the conference. SMA (spinal muscular atrophy) is a rare, devastating motor neuron…

Isis Pharmaceuticals Receives $2.15M To Advance ISIS-SMN Rx In Children With SMA

Isis Pharmaceuticals recently announced it received $2.15 million from Biogen to advance CHERISH, the ongoing pivotal Phase 3 study assessing ISIS-SMNRx in children suffering with spinal muscular atrophy (SMA). Isis has now received over $120 million from Biogen to advance this investigational therapy. CHERISH a Phase 3 ISIS-SMNRx study; it is a double-blinded, randomized, 15 month study in almost 120…